About DURECT Corporation (NASDAQ:DRRX)
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NASDAQ:DRRX
- CUSIP: N/A
- Web: www.durect.com
- Debt-to-Equity Ratio: 1.46%
- Current Ratio: 1.67%
- Quick Ratio: 1.57%
Sales & Book Value:
- Annual Sales: $14.02 million
- Price / Sales: 10.70
- Book Value: $0.07 per share
- Price / Book: 14.43
- Trailing EPS: ($0.15)
- Net Income: ($34,500,000.00)
- Net Margins: -62.57%
- Return on Equity: -419.65%
- Return on Assets: -45.77%
- Employees: 98
- Outstanding Shares: 148,550,000
Frequently Asked Questions for DURECT Corporation (NASDAQ:DRRX)
What is DURECT Corporation's stock symbol?
DURECT Corporation trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT Corporation's earnings last quarter?
DURECT Corporation (NASDAQ:DRRX) issued its quarterly earnings results on Wednesday, November, 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.09. The specialty pharmaceutical company had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. DURECT Corporation had a negative return on equity of 419.65% and a negative net margin of 62.57%. View DURECT Corporation's Earnings History.
When will DURECT Corporation make its next earnings announcement?
Where is DURECT Corporation's stock going? Where will DURECT Corporation's stock price be in 2017?
3 brokerages have issued twelve-month price targets for DURECT Corporation's stock. Their forecasts range from $2.00 to $3.00. On average, they expect DURECT Corporation's share price to reach $2.67 in the next twelve months. View Analyst Ratings for DURECT Corporation.
Are investors shorting DURECT Corporation?
DURECT Corporation saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,657,739 shares, an increase of 40.3% from the October 13th total of 1,181,204 shares. Based on an average trading volume of 1,709,988 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.2% of the shares of the stock are sold short.
Who are some of DURECT Corporation's key competitors?
Some companies that are related to DURECT Corporation include Circassia Pharmaceuticals PLC (CIR), Arrowhead Pharmaceuticals (ARWR), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Pieris Pharmaceuticals (PIRS), Catalyst Pharmaceuticals (CPRX), Vascular Biogenics (VBLT), Faron Pharmaceuticals Oy (FARN), Ovid Therapeutc (OVID), Vital Therapies (VTL), Zymeworks (ZYME), Athersys (ATHX), Threshold Pharmaceuticals (MTEM), Immune Design Corp. (IMDZ), Foamix Pharmaceuticals (FOMX), Selecta Biosciences (SELB), Spring Bank Pharmaceuticals (SBPH) and Chimerix (CMRX).
Who are DURECT Corporation's key executives?
DURECT Corporation's management team includes the folowing people:
- Felix D Theeuwes, Chairman, Chief Scientific Officer (Age 78)
- James E. Brown DVM, President, Chief Executive Officer and Director (Age 58)
- Matthew J. Hogan, Chief Financial Officer (Age 55)
- Judy R. Joice, Senior Vice President - Operations and Corporate Quality Assurance (Age 58)
- Myriam Theeuwes, Senior Vice President - Clinical Development
- David R. Hoffmann, Lead Independent Director (Age 70)
- Simon X. Benito, Independent Director (Age 72)
- Terrence F. Blaschke M.D., Independent Director (Age 72)
- Armand P. Neukermans Ph.D., Independent Director (Age 74)
- Jon S. Saxe J.D., Independent Director (Age 80)
Who owns DURECT Corporation stock?
DURECT Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tocqueville Asset Management L.P. (1.39%), Mangrove Partners (0.86%), Asymmetry Capital Management L.P. (604,215.65%) and Schwab Charles Investment Management Inc. (0.18%). Company insiders that own DURECT Corporation stock include April Fund Lp 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Institutional Ownership Trends for DURECT Corporation.
Who sold DURECT Corporation stock? Who is selling DURECT Corporation stock?
Who bought DURECT Corporation stock? Who is buying DURECT Corporation stock?
DURECT Corporation's stock was bought by a variety of institutional investors in the last quarter, including Mangrove Partners, Tocqueville Asset Management L.P. and Schwab Charles Investment Management Inc.. Company insiders that have bought DURECT Corporation stock in the last two years include April Fund Lp 21, Armand Neukermans, Dave Hoffmann, Felix Theeuwes and James E Brown. View Insider Buying and Selling for DURECT Corporation.
How do I buy DURECT Corporation stock?
Shares of DURECT Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT Corporation's stock price today?
One share of DURECT Corporation stock can currently be purchased for approximately $1.01.
How big of a company is DURECT Corporation?
DURECT Corporation has a market capitalization of $141.92 million and generates $14.02 million in revenue each year. The specialty pharmaceutical company earns ($34,500,000.00) in net income (profit) each year or ($0.15) on an earnings per share basis. DURECT Corporation employs 98 workers across the globe.
How can I contact DURECT Corporation?
DURECT Corporation's mailing address is 10260 Bubb Rd, CUPERTINO, CA 95014-4166, United States. The specialty pharmaceutical company can be reached via phone at +1-408-7771417.
MarketBeat Community Rating for DURECT Corporation (NASDAQ DRRX)MarketBeat's community ratings are surveys of what our community members think about DURECT Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for DURECT Corporation (NASDAQ:DRRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 2 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$2.67 (164.03% upside)|
Consensus Price Target History for DURECT Corporation (NASDAQ:DRRX)
Analysts' Ratings History for DURECT Corporation (NASDAQ:DRRX)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/2/2017||HC Wainwright||Reiterated Rating||Hold||N/A|
|10/20/2017||Laidlaw||Lower Price Target||Buy -> Buy||$3.00 -> $2.00||N/A|
|10/20/2017||Stifel Nicolaus||Downgrade||Buy -> Hold||N/A|
|9/27/2016||Rodman & Renshaw||Reiterated Rating||Buy||$4.00 -> $3.50||N/A|
Earnings History and Estimates Chart for DURECT Corporation (NASDAQ:DRRX)
Earnings History by Quarter for DURECT Corporation (NASDAQ DRRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/13/2018|| || || || || || || || |
|11/1/2017||Q3 2017||($0.05)||$0.04||$5.09 million||$20.75 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.07)||$5.17 million||$4.32 million||View||Listen|
|5/10/2017||Q1 2017||($0.06)||($0.06)||$3.60 million||$4.57 million||View||N/A|
|3/14/2017||Q4 2016||($0.06)||($0.06)||$3.03 million||$3.52 million||View||N/A|
|10/31/2016||Q316||($0.07)||($0.06)||$3.72 million||$37.00 million||View||Listen|
|8/1/2016||Q216||($0.06)||($0.07)||$3.69 million||$3.20 million||View||Listen|
|5/5/2016||Q116||($0.06)||($0.06)||$4.09 million||$3.60 million||View||Listen|
|2/29/2016||Q415||($0.06)||($0.05)||$4.83 million||$5.20 million||View||Listen|
|11/2/2015||Q315||($0.05)||($0.05)||$5.08 million||$4.70 million||View||Listen|
|8/3/2015||Q215||($0.06)||($0.05)||$5.01 million||$4.40 million||View||Listen|
|4/30/2015||Q115||($0.06)||($0.04)||$4.82 million||$4.77 million||View||Listen|
|3/2/2015||Q414||($0.05)||($0.05)||$4.32 million||$4.30 million||View||Listen|
|11/3/2014||Q3||($0.05)||($0.06)||$4.10 million||$4.26 million||View||Listen|
|8/7/2014||Q2||($0.05)||($0.05)||$3.90 million||$4.58 million||View||Listen|
|5/1/2014||Q1||($0.05)||($0.03)||$4.12 million||$6.30 million||View||Listen|
|2/27/2014||Q4||($0.06)||($0.05)||$2.79 million||$4.30 million||View||Listen|
|8/5/2013||Q2 2013||($0.05)||($0.05)||$3.42 million||$3.92 million||View||Listen|
Earnings Estimates for DURECT Corporation (NASDAQ:DRRX)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for DURECT Corporation (NASDAQ:DRRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for DURECT Corporation (NASDAQ DRRX)
Insider Ownership Percentage: 10.30%
Institutional Ownership Percentage: 46.00%
Insider Trades by Quarter for DURECT Corporation (NASDAQ DRRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/3/2016||April Fund L.P. 21||Major Shareholder||Buy||95,000||$1.16||$110,200.00|| |
|9/26/2016||April Fund L.P. 21||Major Shareholder||Buy||2,500,000||$1.15||$2,875,000.00|| |
|4/26/2016||April Fund L.P. 21||Major Shareholder||Buy||5,500,000||$1.25||$6,875,000.00|| |
|4/26/2016||Dave Hoffmann||Director||Buy||200,000||$1.25||$250,000.00|| |
|4/26/2016||Felix Theeuwes||Chairman||Buy||160,000||$1.25||$200,000.00|| |
|3/14/2016||Armand Neukermans||Director||Buy||18,000||$1.39||$25,020.00|| |
|3/14/2016||Felix Theeuwes||Chairman||Buy||70,000||$1.41||$98,700.00|| |
|3/10/2016||James E Brown||CEO||Buy||20,000||$1.33||$26,600.00|| |
|1/11/2016||April Fund Lp 21||Major Shareholder||Buy||300,100||$1.37||$411,137.00|| |
|9/29/2015||April Fund Ltd 21||Major Shareholder||Buy||952,249||$1.79||$1,704,525.71|| |
|3/10/2015||Simon X Benito||Director||Buy||40,000||$1.81||$72,400.00|| |
|3/9/2015||Felix Theeuwes||Chairman||Buy||225,600||$1.65||$372,240.00|| |
|3/6/2015||Felix Theeuwes||Chairman||Buy||380,000||$1.57||$596,600.00|| |
|11/21/2014||Felix Theeuwes||Chairman||Buy||72,700||$1.00||$72,700.00|| |
|11/20/2014||Felix Theeuwes||Chairman||Buy||136,015||$0.92||$125,133.80|| |
|11/8/2013||Felix Theeuwes||Chairman||Buy||714,285||$1.40||$999,999.00|| |
|9/10/2013||Felix Theeuwes||Chairman||Buy||75,000||$1.20||$90,000.00|| |
|9/9/2013||Felix Theeuwes||Chairman||Buy||25,000||$1.15||$28,750.00|| |
|6/4/2013||James E Brown||CEO||Buy||30,000||$0.80||$24,000.00|| |
|12/12/2012||Jon S Saxe||Director||Buy||15,000||$0.91||$13,650.00|| |
|11/14/2012||Felix Theeuwes||Chairman||Buy||100,000||$1.01||$101,000.00|| |
|8/28/2012||Jon S Saxe||Director||Buy||7,810||$0.97||$7,575.70|| |
|8/23/2012||Jon S Saxe||Director||Buy||5,000||$1.00||$5,000.00|| |
Headline Trends for DURECT Corporation (NASDAQ:DRRX)
Latest Headlines for DURECT Corporation (NASDAQ DRRX)
|The Stock Market Cycle And Implications For Medical Stock Investing|
seekingalpha.com - November 14 at 6:27 PM
|Financial Survey: MacroGenics (MGNX) and DURECT Corporation (DRRX)|
www.americanbankingnews.com - November 13 at 3:59 PM
|DURECT Corporation (DRRX) Sees Large Increase in Short Interest|
www.americanbankingnews.com - November 13 at 3:34 AM
|DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017|
finance.yahoo.com - November 10 at 10:46 AM
|DURECT Corporation (DRRX) to Post FY2017 Earnings of ($0.13) Per Share, Zacks Investment Research Forecasts|
www.americanbankingnews.com - November 6 at 6:14 AM
|$4.72 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter|
www.americanbankingnews.com - November 3 at 6:08 AM
|DRRX: Focus will be Shifted to DUR-928 Programs|
finance.yahoo.com - November 2 at 7:04 PM
|DURECT Corp (DRRX) Tops Q3 EPS by 10c - StreetInsider.com|
www.streetinsider.com - November 2 at 5:07 AM
|Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT|
finance.yahoo.com - November 2 at 5:07 AM
|DURECT's (DRRX) CEO James Brown on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 2 at 12:04 AM
|DURECT Corporation (DRRX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS|
www.americanbankingnews.com - November 1 at 8:34 PM
|DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - November 1 at 7:01 PM
|Durect tops Street 3Q forecasts|
finance.yahoo.com - November 1 at 7:01 PM
|FY2018 EPS Estimates for DURECT Corporation Reduced by Analyst (DRRX)|
www.americanbankingnews.com - October 27 at 5:48 PM
|DURECT Corporation Invites You to Join its Third Quarter 2017 ... - PR Newswire (press release)|
www.prnewswire.com - October 26 at 11:57 PM
|DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call|
finance.yahoo.com - October 26 at 6:54 PM
|ETFs with exposure to DURECT Corp. : October 26, 2017|
finance.yahoo.com - October 26 at 1:51 PM
|Durect Takes A Beating On Pain Drug, Still holds Enormous Potential Value - Seeking Alpha|
seekingalpha.com - October 23 at 6:29 PM
|DURECT Co. (DRRX) to Release Quarterly Earnings on Monday|
www.americanbankingnews.com - October 23 at 10:56 AM
|UPDATE: H.C. Wainwright Downgrades Durect Corp (DRRX) to Neutral|
www.streetinsider.com - October 21 at 5:20 PM
|DURECT Corporation (DRRX) Cut to Hold at Stifel Nicolaus|
www.americanbankingnews.com - October 21 at 3:34 PM
|HC Wainwright Lowers DURECT Corporation (DRRX) to Neutral|
www.americanbankingnews.com - October 21 at 2:58 PM
|DURECT Corporation (DRRX) Cut to "Strong Sell" at ValuEngine|
www.americanbankingnews.com - October 21 at 10:40 AM
|Mid-Day Market Update: Dow Surges Over 100 Points; DURECT ... - Nasdaq|
www.nasdaq.com - October 21 at 5:36 AM
|DURECT's pain med Posimir flunks late-stage study; shares plummet 55% premarket - Seeking Alpha|
seekingalpha.com - October 21 at 5:36 AM
|UPDATE: Durect Corp (DRRX) PT Lowered to $2 at Laidlaw - StreetInsider.com|
www.streetinsider.com - October 21 at 5:36 AM
|Pre-Open Stock Movers 10/20: (SKX) (TEAM) (QURE) Higher; (DRRX) (NCR) (CELG) (GE) Lower (more...)|
www.streetinsider.com - October 20 at 7:31 PM
|DURECT Corporation (DRRX) Shares Collapse – Here’s Why|
finance.yahoo.com - October 20 at 7:31 PM
|Laidlaw Trims DURECT Corporation (DRRX) Target Price to $2.00|
www.americanbankingnews.com - October 20 at 10:12 AM
|DURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses ... - StreetInsider.com|
www.streetinsider.com - October 19 at 11:38 PM
|DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint|
finance.yahoo.com - October 19 at 6:36 PM
|ETFs with exposure to DURECT Corp. : October 16, 2017|
finance.yahoo.com - October 16 at 6:41 PM
|Zacks: Brokerages Anticipate DURECT Corporation (DRRX) Will Announce Quarterly Sales of $5.09 Million|
www.americanbankingnews.com - October 15 at 8:06 AM
|DURECT Corporation (DRRX) Expected to Announce Earnings of -$0.05 Per Share|
www.americanbankingnews.com - October 13 at 12:12 PM
|$5.09 Million in Sales Expected for DURECT Corporation (DRRX) This Quarter|
www.americanbankingnews.com - October 12 at 10:54 AM
|Zacks: Brokerages Expect DURECT Corporation (DRRX) Will Post Earnings of -$0.05 Per Share|
www.americanbankingnews.com - October 10 at 8:20 PM
|Comparing DURECT Corporation (DRRX) & Atara Biotherapeutics (ATRA)|
www.americanbankingnews.com - October 8 at 10:38 AM
|ETFs with exposure to DURECT Corp. : October 5, 2017|
finance.yahoo.com - October 5 at 5:12 PM
|Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia|
finance.yahoo.com - October 5 at 10:08 AM
|DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017|
finance.yahoo.com - October 4 at 10:55 AM
|DURECT Corp (DRRX) Announces $12.5M Patent Purchase Agreement with Indivior UK Limited - StreetInsider.com|
www.streetinsider.com - October 3 at 5:55 PM
|DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC|
finance.yahoo.com - October 3 at 5:55 PM
|Short Interest in DURECT Corporation (DRRX) Drops By 23.5%|
www.americanbankingnews.com - October 1 at 1:18 AM
|DURECT Corporation (DRRX) & MannKind Corporation (MNKD) Critical Review|
www.americanbankingnews.com - September 22 at 4:26 PM
|DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development|
finance.yahoo.com - September 20 at 6:53 PM
|Head to Head Review: DURECT Corporation (DRRX) vs. Its Peers|
www.americanbankingnews.com - September 16 at 10:32 AM
|Durect (DRRX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow|
seekingalpha.com - September 13 at 7:20 PM
|2017: The Biopharma Summer Of Love|
seekingalpha.com - September 8 at 6:26 PM
|DURECT to Participate in Upcoming Healthcare Conferences|
finance.yahoo.com - September 5 at 7:34 PM
|DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States|
finance.yahoo.com - August 10 at 7:16 PM
DURECT Corporation (NASDAQ DRRX) Chart for Saturday, November, 18, 2017